TY - JOUR
T1 - Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
JO - Rheumatology (Oxford)
PY - 2008/02/01
AU - Wailoo A
AU - Bansback N
AU - Chilcott J
ED -
DO - DOI: 10.1093/rheumatology/kem294
VL - 47
IS - 2
SP - 119
EP - 120
Y2 - 2025/07/27
ER -